About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The main characteristic of our group is its multidisciplinary nature, as it is comprised of neuroradiologists, technologists, and a physicist, engineer, and biochemist.
The main objectives of our projects are to gain knowledge about the pathophysiologic mechanisms implicated in several neurological diseases and to evaluate new biomarkers and therapies through the use of qualitative and quantitative magnetic resonance (MR) and computed tomography (CT) techniques, and by applying artificial intelligence tools to create prognostic models. Our focus is on the study of diseases such as multiple sclerosis, epilepsy, neuro-oncology, and stroke.
In addition, because of the experience we have acquired along the years in performing MR studies, we act as a platform for designing MR-based projects, processing images, and conducting quantitative data analysis.
PMID: 37775266 Journal: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY Year: 2023 Reference: J Neurol Neurosurg Psychiatry. 2023 Sep 29:jnnp-2023-331920. doi: 10.1136/jnnp-2023-331920. Impact factor: Publication type: Paper in international publication Authors: Al-Araji, Sarmad; Annovazzi, Pietro Osvaldo; Barkhof, Frederik; Bisecco, Alvino; Ciccarelli, Olga; Ciccarelli, Olga; De Stefano, Nicola; Enzinger, Christian; Enzinger, Christian; Evangelou, Nikos et al. DOI: 10.1136/jnnp-2023-331920
PMID: 37803817 Journal: JOURNAL OF MAGNETIC RESONANCE IMAGING Year: 2023 Reference: J Magn Reson Imaging. 2023 Oct 6. doi: 10.1002/jmri.29046. Impact factor: Publication type: Paper in international publication Authors: Alberich, Manel; Alberich, Manel; Arrambide, Georgina; Auger, Cristina; Auger, Cristina; Carbonell-Mirabent, Pere; Castillo, Joaqui N; Cobo-Calvo, Alvaro; Cobo-Calvo, Alvaro; Coll, Llucia et al. DOI: 10.1002/jmri.29046
PMID: 37862240 Journal: JNCI cancer spectrum Year: 2023 Reference: JNCI Cancer Spectr. 2023 Oct 20:pkad088. doi: 10.1093/jncics/pkad088. Impact factor: Publication type: Paper in international publication Authors: Aguado-Barrera, Miguel E; Alizadeh, Behrooz Z; Alsner, Jan; Altabas, Manuel; Andreassen, Christian Nicolaj; Azria, David; Barnett, Gillian C; Bates, Amy M; Bultijnck, Renee; Burnet, Neil G et al. DOI: 10.1093/jncics/pkad088
PMID: 37973633 Journal: EUROPEAN RADIOLOGY Year: 2023 Reference: Eur Radiol. 2023 Nov 16. doi: 10.1007/s00330-023-10416-6. Impact factor: Publication type: Editorail in international publication Authors: Arntzen, Ellen Christin; Coote, Susan; Jonsdottir, Johanna; Kalron, Alon; Kos, Daphne; Learmonth, Yvonne C; Moumdjian, Lousin; Nedeljkovic, Una; Novotna, Klara; Pareto, Deborah et al. DOI: 10.1007/s00330-023-10416-6
Els doctors Xavier Montalban, Àlex Rovira i Mar Tintoré han estat reconeguts en la categoria de Neurociències i Comportament, i el doctor Jordi Rello en la categoria Interdisciplinària.
The program, promoted by Biocat in collaboration with CIMIT (Boston), is aimed at entrepreneurs in the process of bringing their technology to market in the next few years.
